Santen Pharmaceutical Co., Ltd.
4536.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.41 | -0.73 | 6.82 | 1.79 |
| FCF Yield | 0.80% | 1.04% | 3.71% | 1.91% |
| EV / EBITDA | 33.55 | 42.49 | 22.80 | 32.32 |
| Quality | ||||
| ROIC | 2.57% | 1.85% | 2.82% | 2.78% |
| Gross Margin | 54.69% | 54.00% | 56.61% | 55.30% |
| Cash Conversion Ratio | 0.73 | 1.31 | 2.15 | 1.58 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.50% | 0.93% | 2.44% | 3.76% |
| Free Cash Flow Growth | -26.31% | -67.36% | 68.29% | -24.11% |
| Safety | ||||
| Net Debt / EBITDA | -1.83 | -4.09 | -3.15 | -2.92 |
| Interest Coverage | 24.91 | 10.11 | 9.38 | 43.16 |
| Efficiency | ||||
| Inventory Turnover | 0.53 | 0.53 | 0.65 | 0.68 |
| Cash Conversion Cycle | 163.96 | 136.31 | 117.85 | 94.25 |